EYPT - Company ID 0001314102
The table below shows EyePoint Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $31.37M | $43.27M | $46.02M | $41.40M | $36.94M | $34.44M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $221.04M | $132.93M | $64.66M | $49.64M | $28.50M | $17.42M |
| SG&A |
EyePoint Pharmaceuticals, Inc. reported annual revenue of $31.37M for fiscal year 2025. That is down 27.5% from $43.27M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.62M (FY 2016) to $31.37M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $51.61M |
| $52.36M |
| $40.10M |
| $34.82M |
| $25.57M |
| $20.73M |
| Operating income | -$243.43M | -$145.85M | -$75.07M | -$99.64M | -$55.28M | -$37.29M |
| Income tax | $279.00K | $90.00K | $83.00K | $0.00 | $0.00 | $0.00 |
| Net income | -$231.96M | -$130.87M | -$70.80M | -$102.25M | -$58.42M | -$45.39M |
| EPS (diluted) | -$3.17 | -$2.32 | -$1.82 | -$2.74 | -$2.03 | - |